Core Viewpoint - Xintiandi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used to prevent and treat iron deficiency anemia, indicating compliance with national drug registration requirements and enhancing the company's product portfolio and market competitiveness [1] Group 1 - The approval for Ferrous Fumarate signifies that the raw material drug meets the relevant regulatory requirements [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1] - Xintiandi engages in the research, production, and sales of pharmaceutical intermediates, raw materials, and formulations across various therapeutic areas including anti-infection, diabetes, cardiovascular diseases, and local anesthesia [1]
新天地化学原料药富马酸亚铁上市获批